GROWTH OPPORTUNITIES IN SYNTHETIC BIOLOGY, LOGIC GATED THERAPIES, RAPID MOLECULAR DIAGNOSTICS AND PEPTIDE SYNTHESIS PLATFORMS

GROWTH OPPORTUNITIES IN SYNTHETIC BIOLOGY, LOGIC GATED THERAPIES, RAPID MOLECULAR DIAGNOSTICS AND PEPTIDE SYNTHESIS PLATFORMS

RELEASE DATE
17-Jun-2022
REGION
Global
Research Code: D759-00-2D-00-00
SKU: HC03550-GL-TA_26630
$950.00
In stock
SKU
HC03550-GL-TA_26630
$950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on synthetic biology innovations around low cost gene synthesis and deployment of gene circuits for drug discovery and in therapies. Cell and gene therapies using logic gated circuits, along with early stage developers of gene circuits for drug discovery applications are covered. In addition advanced peptide design platforms and high throughput DNA synthesis platform has been covered. A rapid and sensitive molecular diagnostic for scalable Covid-19 testing, which can be adapted at PoC has also been discussed.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: CAR-T cell therapy, cancer immunotherapy, gene circuits, synthetic biology, drug discovery , small molecules, kinase inhibitors, cancer therapeutics, gene therapy, hematology, sickle cell disease, antibody drug conjugate (ADC), antibodies, tumor microenvironment, targeted cancer therapy, microbiome therapeutics, genetic testing, molecular diagnostics, rapid PCR, logic gated therapy, diagnostics, peptide synthesis, DNA synthesis, peptide design, AI, synthetic biotics, engineered microbes.

Table of Contents

INNOVATIONS IN SYNTHETIC BIOLOGY AND VARIOUS THERAPIES

  • NEXT-GENERATION (NEXTGEN) BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
  • IMMPACT BIO—VALUE PROPOSITION
  • IMMPACT BIO—INVESTOR DASHBOARD
  • DEVELOPING BASE EDITORS TO TREAT RARE DISEASES
  • BEAM THERAPEUTICS’ VALUE PROPOSITION
  • BEAM THERAPEUTICS—INVESTOR DASHBOARD
  • SYNTHETIC MICROBE THERAPEUTICS WITH PROGRAMMABLE SWITCHES
  • VALUE PROPOSITION OF SYNLOGIC
  • SYNLOGIC—INVESTOR DASHBOARD
  • PROGRAMMABLE GENE THERAPIES USING LOGIC GATES
  • VALUE PROPOSITION OF PATTERN BIOSCIENCES
  • PATTERN BIOSCIENCES—INVESTOR DASHBOARD
  • IMPROVED T-CELL THERAPIES FOR SOLID TUMOR TREATMENT
  • VALUE PROPOSITION OF ARSENALBIO
  • ARSENALBIO—INVESTOR DASHBOARD
  • EPIGENETIC PLATFORM FOR GENE SILENCING WITHOUT DNA DAMAGE
  • VALUE PROPOSITION OF UNIVERSITY OF CALIFORNIA AND MIT
  • RNA THERAPEUTIC SWITCHES FOR IMPROVED CONTROL OF OUTCOME
  • VALUE PROPOSITION—WYSS INSTITUTE FOR BIOLOGICALLY INSPIRED ENGINEERING AT HARVARD UNIVERSITY
  • TECHNOLOGY LEVERAGING TUMOR CELLS AGAINST CANCER
  • GENE CIRCUITS ENABLING IMMUNOTHERAPY FOR CANCER
  • CIRCUIT BIO—INVESTOR DASHBOARD
  • TECHNOLOGY ENABLING GENE CIRCUIT CONSTRUCTION
  • NEXT-GENERATION GENE SYNTHESIS CREATING LARGE DNA CONSTRUCTS
  • SYNBIO TECHNOLOGIES—INVESTOR DASHBOARD
  • RAPID, COST-EFFECTIVE AND SCALABLE IN VITRO DIAGNOSTIC PLATFORM FOR COVID-19 STRAINS
  • MASS SCREENING POSSIBLE FROM A SINGLE INSTRUMENT WITH HIGH ACCURACY
  • GENES2ME PVT. LTD.— INVESTOR DASHBOARD
  • PEPTIDE MOLECULE SYNTHESIS FOR DRUG DISCOVERY
  • PEPTIDREAM—VALUE PROPOSITION
  • PEPTIDREAM—INVESTOR DASHBOARD
  • AI-BASED PEPTIDE MANUFACTURING
  • MYTIDE—VALUE PROPOSITION
  • MYTIDE—INVESTOR DASHBOARD
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • LEGAL DISCLAIMER
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on synthetic biology innovations around low cost gene synthesis and deployment of gene circuits for drug discovery and in therapies. Cell and gene therapies using logic gated circuits, along with early stage developers of gene circuits for drug discovery applications are covered. In addition advanced peptide design platforms and high throughput DNA synthesis platform has been covered. A rapid and sensitive molecular diagnostic for scalable Covid-19 testing, which can be adapted at PoC has also been discussed. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: CAR-T cell therapy, cancer immunotherapy, gene circuits, synthetic biology, drug discovery , small molecules, kinase inhibitors, cancer therapeutics, gene therapy, hematology, sickle cell disease, antibody drug conjugate (ADC), antibodies, tumor microenvironment, targeted cancer therapy, microbiome therapeutics, genetic testing, molecular diagnostics, rapid PCR, logic gated therapy, diagnostics, peptide synthesis, DNA synthesis, peptide design, AI, synthetic biotics, engineered microbes.
More Information
Industries Healthcare
No Index No
Is Prebook No
Podcast No
Ti Codes D759
WIP Number D759-00-2D-00-00